Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-wo
- PDF / 529,006 Bytes
- 11 Pages / 595.276 x 790.866 pts Page_size
- 71 Downloads / 154 Views
ORIGINAL ARTICLE—LIVER, PANCREAS, AND BILIARY TRACT
Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study Yuki Tahata1 • Hayato Hikita1 • Satoshi Mochida2 • Norifumi Kawada3 • Nobuyuki Enomoto4 • Akio Ido5 • Hitoshi Yoshiji6 • Daiki Miki7 • Yoichi Hiasa8 • Yasuhiro Takikawa9 • Ryotaro Sakamori1 • Masayuki Kurosaki10 • Hiroshi Yatsuhashi11 • Ryosuke Tateishi12 • Yoshiyuki Ueno13 • Yoshito Itoh14 • Taro Yamashita15 • Tatsuya Kanto16 • Goki Suda17 • Yasunari Nakamoto18 • Naoya Kato19 • Yasuhiro Asahina20 • Kentaro Matsuura21 • Shuji Terai22 • Kazuhiko Nakao23 • Masahito Shimizu24 • Taro Takami25 • Norio Akuta26 • Ryoko Yamada1 • Takahiro Kodama1 • Tomohide Tatsumi1 • Tomomi Yamada27 Tetsuo Takehara1
•
Received: 27 May 2020 / Accepted: 18 September 2020 Ó Japanese Society of Gastroenterology 2020
Abstract Background Real-world data on the efficacy and safety of sofosbuvir plus velpatasvir (SOF/VEL) treatment for
Electronic supplementary material The online version of this article (https://doi.org/10.1007/s00535-020-01733-4) contains supplementary material, which is available to authorized users. & Tetsuo Takehara [email protected] 1
2
3
4
5
6
7
8
patients with hepatitis C virus (HCV)-related decompensated cirrhosis are limited in Japan. Methods A total of 190 patients with compensated (108) or decompensated (82) cirrhosis who initiated direct-acting antiviral (DAA) treatment between February 2019 and August 2019 were enrolled. Sustained virologic response (SVR) was defined as undetectable serum HCV-RNA at 12 weeks after the end of treatment (EOT). 9
Division of Hepatology, Department of Internal Medicine, Iwate Medical University, Iwate, Japan
10
Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan
Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan
11
Department of Gastroenterology and Hepatology, Saitama Medical University, Saitama, Japan
Clinical Research Center, National Hospital Organization Nagasaki Medical Center, Nagasaki, Japan
12
Department of Hepatology, Graduate School of Medicine, Osaka City University, Osaka, Japan
Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
13
Department of Gastroenterology, Faculty of Medicine, Yamagata University, Yamagata, Japan
14
Digestive and Lifestyle Diseases, Department of Human and Environmental Sciences, Kagoshima University Graduate School of Medicine and Dental Sciences, Kagoshima, Japan
Department of Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan
15
Department of Gastroenterology, Nara Medical University, Nara, Japan
Department of General Medicine, Kanazawa University Hospital, Kanazawa, Japan
16
The Research Center for Hepatitis and Immunology, National Center for Global Health and M
Data Loading...
